Medical/Pharmaceuticals
Professor Wong Tin Chee Honored as GQ Hong Kong's Local Hero 2025 Giving Back to Society with TCM Wisdom Launches "The Pain Management CEO" Video Series Sharing the Path to Self-Management of Pain Conditions
HONG KONG, Jan. 9, 2026 /PRNewswire/ -- Wong Tin-Chee, Founder of Herbalgy Pharmaceutical Ltd. and Professor of Traditional Chinese Medicine, has been honored as one of the Local Heroes in GQ Hong Kong's Men of the Year 2025, in recognition of his long-standing commitment to advancing pain manage...
2026-01-09 10:00
3889
Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference
MELBOURNE, Australia and INDIANAPOLIS, Jan. 8, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference being held in Sa...
2026-01-08 19:00
3613
From Quantified Meditation to Bio-Computing, All Here Launches the Bio-Intelligence Initiative
GENEVA, Jan. 8, 2026 /PRNewswire/ -- All Here announces the launch of the Bio-Intelligence Initiative, the world's first research program exploring how deep meditative states of stability and silence of Mind give rise to measurable neural patterns, and how these complex neural signatures may insp...
2026-01-08 18:48
3589
Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD
SHANGHAI, Jan. 8, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced thatChina's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and Dexmethylphenidate Hydrochloride Capsules (Aizhida) f...
2026-01-08 17:58
3191
STARMED Unveils New Brand Identity to Drive Global Multi-Modality Strategy
SEOUL, South Korea, Jan. 8, 2026 /PRNewswire/ -- STARMED, a pioneer in innovative minimally invasive treatment solutions, has announced a comprehensive rebranding. Now in its seventeenth year of operation, the company is formally transitioning from a Radiofrequency Ablation (RFA) specialist into ...
2026-01-08 10:41
3198
Sky Labs Secures CE-MDR for 'CART PLATFORM,' Accelerating Its Global Market Entry
- 'CART,' the blood pressure ring, recognized in Europe for its advanced vital sign monitoring technology - Targeting the global healthcare market beyond Europe through CE-MDR certification SEOUL, South Korea, Jan. 8, 2026 /PRNewswire/ -- Sky Labs (CEO Jack Byunghwan Lee) announced on the 8th th...
2026-01-08 09:15
2915
'Scripting Possibilities' in Biotechnology: Global Innovators Converge in San Francisco for GenScript's 5th Annual Biotech Forum During JPM Week
PISCATAWAY, N.J., Jan. 6, 2026 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, is proud to announce its 5th Annual Biotech Global Forum, scheduled for January 14, 2026, at the San Francisco Marriott Marquis, with both in-person and v...
2026-01-06 21:30
3634
Healthcare Holding Schweiz Acquires Stake in Medddbase International
Healthcare Holding Schweiz AG, a leading service provider and distributor of medical technology inSwitzerland, expands its portfolio through the acquisition of a majority stake in Medddbase International AG, which includes Medddbase Schweiz AG and Medddbase Deutschland GmbH. Healthcare Holding Sc...
2026-01-06 19:19
4595
Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
Anticipated advancements in weight loss, diabetes, oncology, rare conditions
and protein degraders poised to reshape patient care
LONDON, Jan. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT
2026-01-06 16:21
3579
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform
SINGAPORE, Jan. 6, 2026 /PRNewswire/ -- Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical's HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP service...
2026-01-06 12:03
5445
Everest Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced thatIan Woo, President and Chief Fina...
2026-01-06 07:58
3954
Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA
CHENGDU, China, Jan. 5, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that its Investigational New Drug (IND) application for SKB105 (also known as CR-003), an internally developed integrin beta-6 (ITGB6)-targeted ant...
2026-01-05 20:00
3748
Sisram Medical Reports Completion of NIFDC Testing for DAXXIFY in China
Marking a Key Milestone Toward Market Launch and Strengthening Sisram's Premium Aesthetics Portfolio HONG KONG, Jan. 5, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the"Group"), a global wellness group off...
2026-01-05 17:36
2722
Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC
CHENGDU, China, Jan. 5, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) in combination wi...
2026-01-05 17:29
4071
GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy
HONG KONG, Jan. 5, 2026 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application...
2026-01-05 12:07
3804
C&R Research, the 'K-Clinical Hub', Strengthens Partnerships in Indonesia
Accelerating Indonesia Collaboration through Global Clinical Capabilities SEOUL, South Korea, Jan. 5, 2026 /PRNewswire/ -- C&R Research, founded in 1997 as Korea's first full-service Contract Research Organization (CRO), has played a pivotal role in advancing the Korean clinical trial industry an...
2026-01-05 10:00
5384
Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes
-The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability of ASC30 in participants with diabetes. Enrollment is expected to begin in the first quarter of 2026. -ASC30 demonstrated placebo-...
2026-01-05 08:10
3449
Babies Bliss Establishes a New Standard for Fertility Wellness in Singapore with a Whole-Person, Cycle-Aware Model
Singapore-based Fertility Wellness House positions complementary care as long-term support alongside IVF and assisted fertility treatments SINGAPORE, Jan. 5, 2026 /PRNewswire/ -- Babies Bliss, a leading fertility wellness house inSingapore, is redefining how fertility journeys are supported thro...
2026-01-05 07:00
3534
Life-Space TrioBiotic Series Lands in Southeast Asia, Revolutionizing Gut Health with Triple-Action Formula
BANGKOK, Dec. 31, 2025 /PRNewswire/ -- A significant shift is underway in the regional health and wellness landscape as the innovative Life-Space TrioBiotic supplement series officially enters the Southeast Asian market. The launch introduces a cutting-edge "three-in-one" approach to gut health, ...
2025-12-31 15:46
7884
KLMBio Accelerates Global Expansion in Bone Graft Market with Human Tissue-Based Medical Devices
SEOUL, South Korea, Dec. 31, 2025 /PRNewswire/ -- KLMBio, a manufacturer and exporter of human tissue-based medical devices, is accelerating its global business expansion by strengthening its high-value tissue-based product portfolio to target the rapidly growing global bone graft market. The gl...
2025-12-31 12:44
3674
Week's Top Stories
Most Reposted
Visa Supports Chinese Cardholders to Add Cards to Apple Pay for a More Convenient and Secure Payment Experience
[Picked up by 310 media titles]
2026-01-15 13:00Ready Server Announces Strategic Expansion into Japan with AT TOKYO Data Centre
[Picked up by 301 media titles]
2026-01-13 13:16
JIOS Aerogel® Secures Hyundai Contract Through New Licensing Model
[Picked up by 296 media titles]
2026-01-15 10:00Infobip strengthens leadership to drive growth and innovation
[Picked up by 281 media titles]
2026-01-16 11:00
NLCS (Singapore) Brings World-Class Musical Opportunities to Young Artists Across Asia
[Picked up by 278 media titles]
2026-01-14 07:00
Most Read
NLCS (Singapore) Brings World-Class Musical Opportunities to Young Artists Across Asia
2026-01-14 07:00
6190
